摘要
目的了解2008年北京市未经抗病毒治疗HIV-1感染者中耐药株传播水平，为耐药监测和临床抗病毒治疗工作提供本底资料。方法参照WHO提出的HIV耐药警戒线调查方法（HIV drug resistance threshold survey，HIVDR－TS）指导方案，收集6个月内检测发现的60～70名小于25岁的感染者血浆样本，检测HIV－1 pol区亚型及耐药基因型，并计算耐药株检出率、评价传播水平。结果61份符合要求的样本共获得50个有效pol区序列。感染途径以同性传播为主，占62％；亚型分布以B（42％）、CRF01_AE（28％）、CRF07_BC（26％）3种为主。出现1例针对PI类药物的耐药突变株，检出率为2％（1／50）；出现1例针对NRTI类药物的耐药突变株，检出率为2％（1／50）；未出现针对NNRTI类药物的耐药突变株，检出率为0。蛋白酶（PR）区和逆转录酶（RT）区的耐药突变株检出率均为2％，均属于低度传播范围（〈5％）。结论北京市未经抗病毒治疗HIV-1感染者中出现PR和RT区的耐药突变株，传播水平尚处于低流行状态，现有的抗病毒治疗方案是可行的，治疗前尚不需要进行大规模耐药性检测。
Objective To study the prevalence of HIV-1 drug-resistant strains in antiretroviral therapy-naive HIV-1 infectors, and provide background information for HIV-1 drug resistance survey and clinical antiretroviral therapy in Beijing in 2008. Methods Referring to the guidelines for HIV drug resistance threshold survey（HIVDR-TS） of WHO, collecting 60-70 plasma samples of HIV-1 infectors who were detected in 6 months and not more than 25 years ,we detected HIV-1 pol genotype and genetic mutations associated with drug resistance, counted the prevalence of drug-resistant strains, and evaluated the prevalent level. Resuits Of 61 plasma samples answering for the standards, 50 were successfully sequenced and genotyped pol sequence. The major infection route was homosex, which accounted for 62%. B, CRF01_AE, and CRF07_ BC were major genetic subtype, which accounted for 42% , 28% and 26%, respectively. One PI-resistant strain was found, the incidence of which was 2% （1/50）. One NRTI-resistant strain was found, the incidence of which was 2% （1/50）. No NRTI-resistant strain was found, the incidence of which was 0. The incidence of drug-resistant strains in the protease （PR） region was 2%, and the incidence of reverse transcriptase （RT） region was also 2%. Both of the prevalence were classified as low level （ 〈5% ）. Conclusion PR, RT-resistant HIV-1 strains were found in drug-naive infectors, and the prevalence was low in Beijing. Current antiretroviral therapy regiments were still feasible. Most of the AIDS patients did not need to test drug resistance before antiretroviral therapy.
出处
《中华微生物学和免疫学杂志》
CAS
CSCD
北大核心
2009年第6期499-502,共4页
Chinese Journal of Microbiology and Immunology
基金
国家高科技“863”课题资助项目（2006AA02Z418）
